Brain natriuretic peptide in patients with acute ischemic stroke: Role of statins
Brain natriuretic peptide in patients with acute ischemic stroke: Role of statins
复制标题
DOI：
10.4103/bbrj.bbrj_44_20
复制
发表时间：
2020-07-01
影响因子：
1.4
通讯作者：
Naji, Marwa Thaier
中科院分区：
文献类型：
--
作者：
Al-Kuraishy, Hayder M.;Al-Gareeb, Ali, I;Naji, Marwa Thaier
背景：急性缺血性卒中（AIS）与脑钠肽（BNP）血清水平紊乱有关。因此，本研究的目的是阐明阿托伐他汀和瑞舒伐他汀对AIS患者BNP的潜在影响。方法：共招募88名接受或未接受他汀类药物治疗的AIS患者，与22名健康对照。AIS患者分为：A组：接受他汀类药物治疗（阿托伐他汀或瑞舒伐他汀）的AIS患者（n = 44）和B组：未接受他汀类药物治疗的AIS患者（n = 22）。测量了体重指数、血压、血脂和血清BNP水平。同时，对所有患者和健康志愿者进行卒中风险评分（SRS）评估。结果：AIS患者血清BNP水平高于健康对照组（P = 0.0006）。未接受他汀类药物治疗的AIS患者（29.96 +/- 17.21 mu g/dL）高于接受他汀类药物治疗的AIS患者（21.66 +/- 14.22 mu g/dL）， P < 0.001。而阿托伐他汀组AIS患者血清BNP水平为（20.33 6.05 mu g/dL），瑞舒伐他汀组AIS患者血清BNP水平为（21.51 +/- 6.82 mu g/dL），差异无统计学意义（P = 0.54）。此外，接受他汀类药物治疗的AIS患者血清BNP水平与SRS相关（r = 0.42， P= 0.03），而未接受他汀类药物治疗的AIS患者血清BNP水平与SRS高度相关（r = 0.89, P < 0.001）。结论：AIS患者血清BNP水平升高，与SRS显著相关。他汀类药物治疗主要是阿托伐他汀和瑞舒伐他汀是通过降低血清BNP水平来治疗AIS的有效抗炎药物。然而，两种他汀类药物之间没有显著差异。
Background: Acute ischemic stroke (AIS) is associated with disturbances in brain natriuretic peptide (BNP) serum levels. Therefore, the objective of this study is to illustrate the potential effects of atorvastatin and rosuvastatin on BNP in patients with AIS. Methods: A total of 88 patients with AIS with or without statins therapy compared with 22 healthy controls were recruited. The patients with AIS were divided into: Group A: Patients with AIS on statins therapy (atorvastatin or rosuvastatin), (n = 44) and Group B: Patients with AIS not were on statins therapy (n = 22). Body mass index, blood pressure profile, lipid profile, and serum levels of human BNP were measured. As well, stroke risk score (SRS) was assessed in all involved patients and healthy volunteers. Results: BNP serum level was higher in patients with AIS compared with healthy controls (P = 0.0006). It was higher in patients with AIS not were on statins therapy (29.96 +/- 17.21 mu g/dL) as compared with patients with AIS on statins therapy (21.66 +/- 14.22 mu g/dL), P < 0.001. However, BNP serum level was (20.33 6.05 mu g/dL) in AIS patients on atorvastatin and (21.51 +/- 6.82 mu g/dL) AIS patients on rosuvastatin, which was not significantly differed (P = 0.54). Moreover, BNP serum levels were correlated with SRS in patients with AIS on statins therapy (r = 0.42, P= 0.03), but it was highly correlated with SRS in patients with AIS not were on statins therapy (r = 0.89, P < 0.001). Conclusion: BNP serum level is elevated in patients with AIS and correlated significantly with SRS. Statins therapy mainly atorvastatin and rosuvastatin are effective anti-inflammatory agents in the management of AIS through the reduction of BNP serum levels. However, there is no significant difference between the two statins.